ABSTRACT
Spondyloarthritis (SpA) comprises a number of inflammatory rheumatic diseases with overlapping clinical manifestations. Strong association with several HLA-I alleles and T cell infiltration into an inflamed joint suggest involvement of T cells in SpA pathogenesis. In this study, we performed high-throughput T cell repertoire profiling of synovial fluid (SF) and peripheral blood (PB) samples collected from a large cohort of SpA patients. We showed that synovial fluid is enriched with expanded T cell clones that are shared between patients with similar HLA genotypes and persist during recurrent synovitis. Using the recently published algorithm we discovered antigen-driven CD8+ clonal groups associated with risk HLA-B*27 or HLA-B*38 alleles. These clonal groups were enriched in SF and had higher frequency in PB of SpA patients vs healthy donors, suggesting their relevance to joint inflammation. Several of the identified groups were shared among patients with ankylosing spondylitis and psoriatic arthritis, suggesting existence of a common immunopathological mechanism of the diseases. In summary, our results provide supporting evidence for the role of antigen-driven CD8+ T cell clones in pathogenesis of SpA.
Competing Interest Statement
The authors declare no conflict of interest affecting the presented results. EL is a member of the Speakers bureau of Janssen. TK is a member of Speakers bureau of: Pfizer, MSD, Novartis, AbbVie, Janssen, Lilly, Celgene, JSC BIOCAD, and Novartis-Sandoz. SE is a member of the Speakers bureau of KRKKA, MCB and JSC BIOCAD. SL and IZ provide scientific advisory service for JSC BIOCAD.
Funding Statement
This work was supported by the Russian Science Foundation grant No 20-75-00041.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Pirogov Russian National Research Medical University (abstract #170 18 Dec 2017)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw sequencing data obtained for the present study are deposited in the ArrayExpress database (E-MTAB-11498)
